Business Wire - Biovail Launches Wellbutrin XL to Canadian Physicians
Tuesday, December 16th, 2008 TORONTO — Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that Wellbutrin(R) XL, the first once-daily extended-release formulation of bupropion hydrochloride approved for the Canadian market for the treatment of depression in adults, has been officially launched and is commercially available.
Wellbutrin(R) XL, is being marketed and distributed by Biovail Pharmaceuticals …
